Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 20 December 1991:
Vol. 254. no. 5039, pp. 1799 - 1802
DOI: 10.1126/science.1763331
Prev | Table of Contents | Next

Articles

Science, Vol 254, Issue 5039, 1799-1802
Copyright © 1991 by American Association for the Advancement of Science

articles

Inhibition of HIV replication in acute and chronic infections in vitro by a Tat antagonist

MC Hsu, AD Schutt, M Holly, LW Slice, MI Sherman, DD Richman, MJ Potash, and DJ Volsky

Department of Virology, Hoffmann-La Roche, Nutley, NJ 07110.

The human immunodeficiency virus-1 (HIV-1) trans-activator Tat is an attractive target for the development of antiviral drugs because inhibition of Tat would arrest the virus at an early stage. The drug Ro 5-3335 [7-chloro-5-(2-pyrryl)-3H-1,4-benzodiazepine-2(H)-one], inhibited gene expression by HIV-1 at the level of transcriptional trans-activation by Tat. The compound did not inhibit the basal activity of the promoter. Both Tat and its target sequence TAR were required for the observed inhibitory activity. Ro 5-3335 reduced the amount of cell-associated viral RNA and antigen in acutely, as well as in chronically infected cells in vitro (median inhibition concentration 0.1 to 1 micromolar). Effective inhibition of viral replication was also observed 24 hours after cells were transfected with infectious recombinant HIV-1 DNA. The compound was active against both HIV-1 and HIV-2 and against 3'-azido-3'-deoxythymidine (AZT)-resistant clinical isolates.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
The up-regulation of ferritin expression using a small-molecule ligand to the native mRNA.
J. D. Tibodeau, P. M. Fox, P. A. Ropp, E. C. Theil, and H. H. Thorp (2006)
PNAS 103, 253-257
   Abstract »    Full Text »    PDF »
A Second Target for the Peptoid Tat/Transactivation Response Element Inhibitor CGP64222: Inhibition of Human Immunodeficiency Virus Replication by Blocking CXC-Chemokine Receptor 4-Mediated Virus Entry.
D. Daelemans, D. Schols, M. Witvrouw, C. Pannecouque, S. Hatse, S. van Dooren, F. Hamy, T. Klimkait, E. de Clercq, and A.-M. VanDamme (2000)
Mol. Pharmacol. 57, 116-124
   Abstract »    Full Text »
Inhibition of Human Immunodeficiency Virus Type 1 Replication in Acutely and Chronically Infected Cells by EM2487, a Novel Substance Produced by a Streptomyces Species.
M. Baba, M. Okamoto, and H. Takeuchi (1999)
Antimicrob. Agents Chemother. 43, 2350-2355
   Abstract »    Full Text »
Inhibition of Human Immunodeficiency Virus Type 1 Replication by Combination of Transcription Inhibitor K-12 and Other Antiretroviral Agents in Acutely and Chronically Infected Cells.
M. Okamoto, T. Okamoto, and M. Baba (1999)
Antimicrob. Agents Chemother. 43, 492-497
   Abstract »    Full Text »
Interactions of Benzodiazepine Derivatives with Annexins.
A. Hofmann, A. Escherich, A. Lewit-Bentley, J. Benz, C. Raguenes-Nicol, F. Russo-Marie, V. Gerke, L. Moroder, and R. Huber (1998)
J. Biol. Chem. 273, 2885-2894
   Abstract »    Full Text »    PDF »
S-Adenosylhomocysteine Hydrolase Inhibitors Interfere with the Replication of Human Immunodeficiency Virus Type 1 through Inhibition of the LTR Transactivation.
D. Daelemans, J. A. Esté, M. Witvrouw, C. Pannecouque, H. Jonckheere, S. Aquaro, C.-F. Perno, E. D. Clercq, and A.-M. Vandamme (1997)
Mol. Pharmacol. 52, 1157-1163
   Abstract »    Full Text »
A new reporter cell line to monitor HIV infection and drug susceptibility in vitro.
A. Gervaix, D. West, L. M. Leoni, D. D. Richman, F. Wong-Staal, and J. Corbeil (1997)
PNAS 94, 4653-4658
   Abstract »    Full Text »    PDF »
Therapy for Human Immunodeficiency Virus Infection.
M. S. Hirsch and R. T. D'Aquila (1993)
N. Engl. J. Med. 328, 1686-1695
   Full Text »
Present status and future prospects for HIV therapies.
M. Johnston and D. Hoth (1993)
Science 260, 1286-1293
   Abstract »    PDF »
The VP16 transcription activation domain is functional when targeted to a promoter-proximal RNA sequence..
L S Tiley, S J Madore, M H Malim, and B R Cullen (1992)
Genes & Dev. 6, 2077-2087
   Abstract »    PDF »
Development of a Functional Backbone Cyclic Mimetic of the HIV-1 Tat Arginine-rich Motif.
A. Friedler, D. Friedler, N. W. Luedtke, Y. Tor, A. Loyter, and C. Gilon (2000)
J. Biol. Chem. 275, 23783-23789
   Abstract »    Full Text »    PDF »
CD8+ T cell-mediated suppressive activity inhibits HIV-1 after virus entry with kinetics indicating effects on virus gene expression.
G. D. Tomaras, S. F. Lacey, C. B. McDanal, G. Ferrari, K. J. Weinhold, and M. L. Greenberg (2000)
PNAS 97, 3503-3508
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)